Mar 29, 2019 / 11:00AM GMT
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to today's AstraZeneca Management Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, Friday, 29th of March 2019.
And without any further delay, I would now like to turn the conference over to presenter today, Chief Executive Officer, Pascal Soriot. Please go ahead, sir.
Pascal Soriot - AstraZeneca PLC - CEO & Executive Director
Thank you, operator. Good morning, good afternoon, everybody. Thank you very much for joining us today. We wanted to share with you a short presentation about the very exciting project we've just announced today. If you move to Slide 2, this is our forward-looking statement. Slide 3, today, I will share the presentation with José Baselga, who is our Executive Vice President of Research and Development Oncology; Dave Fredrickson, who is our EVP of Oncology; and Marc Dunoyer, our CFO.
If we move to Slide 4, which is a summary of the deal we've announced, we see DS-8201 as a transformative
AstraZeneca PLC to Discuss Strategic Collaboration in Oncology of Trastuzumab Deruxtecan (DS-8201) with Daiichi Sankyo Co Ltd Call Transcript
Mar 29, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers